Haemonetics Statistics
Share Statistics
Haemonetics has 50.24M
shares outstanding. The number of shares has increased by -1.4%
in one year.
| Shares Outstanding | 50.24M |
| Shares Change (YoY) | -1.4% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 4.43M, so 8.82% of the outstanding
shares have been sold short.
| Short Interest | 4.43M |
| Short % of Shares Out | 8.82% |
| Short % of Float | 13.95% |
| Short Ratio (days to cover) | 4.93 |
Valuation Ratios
The PE ratio is 36.81 and the forward
PE ratio is 12.96.
Haemonetics's PEG ratio is
16.71.
| PE Ratio | 36.81 |
| Forward PE | 12.96 |
| PS Ratio | 3.31 |
| Forward PS | 2.1 |
| PB Ratio | 4.51 |
| P/FCF Ratio | 37.48 |
| PEG Ratio | 16.71 |
Financial Ratio HistoryEnterprise Valuation
Haemonetics has an Enterprise Value (EV) of 4.96B.
| EV / Sales | 3.79 |
| EV / EBITDA | 18.66 |
| EV / EBIT | 27.27 |
| EV / FCF | 42.93 |
Financial Position
The company has a current ratio of 2.56,
with a Debt / Equity ratio of 0.84.
| Current Ratio | 2.56 |
| Quick Ratio | 1.5 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | 3.04 |
| Debt / FCF | 7 |
| Interest Coverage | 12.67 |
Financial Efficiency
Return on Equity is 12.25% and Return on Invested Capital is 6.7%.
| Return on Equity | 12.25% |
| Return on Assets | 5.35% |
| Return on Invested Capital | 6.7% |
| Revenue Per Employee | $357,958.71 |
| Profits Per Employee | $32,146.02 |
| Employee Count | 3,657 |
| Asset Turnover | 0.6 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | 34.31M |
| Effective Tax Rate | 22.59% |
Stock Price Statistics
The stock price has increased by -26.59% in the
last 52 weeks. The beta is 0.32, so Haemonetics's
price volatility has been higher than the market average.
| Beta | 0.32 |
| 52-Week Price Change | -26.59% |
| 50-Day Moving Average | 63.12 |
| 200-Day Moving Average | 73.68 |
| Relative Strength Index (RSI) | 66.87 |
| Average Volume (20 Days) | 834,954 |
Income Statement
In the last 12 months, Haemonetics had revenue of 1.31B
and earned 117.56M
in profits. Earnings per share was 2.32.
| Revenue | 1.31B |
| Gross Profit | 691.55M |
| Operating Income | 164.88M |
| Net Income | 117.56M |
| EBITDA | 265.58M |
| EBIT | 164.88M |
| Earnings Per Share (EPS) | 2.32 |
Full Income StatementBalance Sheet
The company has 178.8M in cash and 807.79M in
debt, giving a net cash position of -628.99M.
| Cash & Cash Equivalents | 178.8M |
| Total Debt | 807.79M |
| Net Cash | -628.99M |
| Retained Earnings | 360.46M |
| Total Assets | 2.53B |
| Working Capital | 752.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 181.75M
and capital expenditures -66.3M, giving a free cash flow of 115.45M.
| Operating Cash Flow | 181.75M |
| Capital Expenditures | -66.3M |
| Free Cash Flow | 115.45M |
| FCF Per Share | 2.28 |
Full Cash Flow StatementMargins
Gross margin is 52.83%, with operating and profit margins of 12.6% and 8.98%.
| Gross Margin | 52.83% |
| Operating Margin | 12.6% |
| Pretax Margin | 11.6% |
| Profit Margin | 8.98% |
| EBITDA Margin | 20.29% |
| EBIT Margin | 12.6% |
| FCF Margin | 8.82% |
